Beraprost + Aspirin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jul 1, 2010 → Jan 1, 2013
NCT ID
NCT02786979About Beraprost + Aspirin
Beraprost + Aspirin is a approved stage product being developed by Astellas Pharma for Type 2 Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT02786979. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02786979 | Approved | Terminated |
Competing Products
20 competing products in Type 2 Diabetes Mellitus